Streptamer technology is a direct selection technique based on multimers, which are macromolecules designed to label or isolate antigen-specific
T cells. We use the technology, under license from Juno Therapeutics GmbH, to manufacture Cytovir® CMV.

The process for each patient begins with the collection of peripheral blood mononuclear cells (PBMCs) from a matched healthy donor. With the help of Streptamers, which consist of MHC class I multimers, we are then able to quickly and accurately select the CD8+ viral-specific T cells and manufacture Cytovir CMV.

After isolation of the target cells, the reagent is completely dissociated from the T cells in a single step using biotin. The isolated T cells are neither activated nor changed by the selection and isolation process and continue to function normally1.